ADAR1 Capital Management »

An2 Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $47k 14k 3.42

More positions owned by ADAR1 Capital Management

Abivax Sa Sponsored Ads (ABVX)
Protagonist Therapeutics (PTGX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Terns Pharmaceuticals Call Option (TERN)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Cytokinetics Com New (CYTK)
Crinetics Pharmaceuticals In (CRNX)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Denali Therapeutics (DNLI)
Beam Therapeutics (BEAM)
Zai Lab Adr (ZLAB)
Septerna (SEPN)
Vir Biotechnology (VIR)
Dbv Technologies S A Sponsored Ads (DBVT)

View all positions for ADAR1 Capital Management

Top funds holding An2 Therapeutics

Vivo Capital
Commodore Capital
Millennium Management
Almitas Capital
Vanguard Group
Vanguard Capital Management
Woodline Partners
Ameriprise Financial
Stonepine Capital Management
Ally Bridge Group
Bank of Nova Scotia
Bank of America Corporation
Renaissance Technologies
BlackRock
Jane Street

View all funds holding An2 Therapeutics